Caris Life Sciences, Inc. (CAI)
25.23
-0.80
(-3.07%)
USD |
NASDAQ |
Nov 06, 16:00
25.15
-0.08
(-0.32%)
After-Hours: 20:00
Caris Life Sciences Research and Development Expense (Quarterly) : 33.84M for Sept. 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 33.84M |
| June 30, 2026 | 32.36M |
| March 31, 2026 | 31.32M |
| December 31, 2025 | 31.84M |
| September 30, 2025 | 21.62M |
| June 30, 2025 | 25.05M |
| Date | Value |
|---|---|
| March 31, 2025 | 23.07M |
| December 31, 2024 | 27.11M |
| September 30, 2024 | 27.64M |
| June 30, 2024 | 24.79M |
| March 31, 2024 | 34.38M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Natera, Inc. | 242.43M |
| Myriad Genetics, Inc. | 26.50M |
| BioRestorative Therapies, Inc. | 1.926M |
| CareDx, Inc. | 21.32M |
| Exagen, Inc. | 1.426M |